Search Results

You are looking at 41 - 50 of 258 items for :

  • "oxaliplatin" x
  • Refine by Access: All x
Clear All
Full access

Yanli Li, Leila Family, Su-Jau Yang, Zandra Klippel, John H. Page, and Chun Chao

California (KPSC), we evaluated FN risks associated with docetaxel/cyclophosphamide (TC) and docetaxel/carboplatin/trastuzumab (TCH) for breast cancer; leucovorin/5-fluorouracil/oxaliplatin (FOLFOX6) or capecitabine/oxaliplatin (XELOX) for colorectal cancer

Full access

David Y. Oh, Alan P. Venook, and Lawrence Fong

(CRC). Chemotherapeutic agents such as oxaliplatin trigger immunogenic cell death, which leads to activation and maturation of dendritic cells (DCs) through release of small molecules, such as HMGB1 and ATP (through autophagy and endoplasmic reticulum

Full access

Brian Vicuna and Al B. Benson III

fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803 . J Clin Oncol 2007 ; 25 : 3456 – 3461 . 51. Kuebler JP Wieand HS O'Connell MJ . Oxaliplatin combined with weekly bolus fluorouracil and

Full access

Andrea Cercek, Karyn A. Goodman, Carla Hajj, Emily Weisberger, Neil H. Segal, Diane L. Reidy-Lagunes, Zsofia K. Stadler, Abraham J. Wu, Martin R. Weiser, Philip B. Paty, Jose G. Guillem, Garrett M. Nash, Larissa K. Temple, Julio Garcia-Aguilar, and Leonard B. Saltz

chemotherapy with the addition of oxaliplatin to 5-fluorouracil (5-FU) have resulted in improved survival in patients with metastatic colorectal cancer and those with stage III colon cancer treated with adjuvant FOLFOX (5-FU, leucovorin, oxaliplatin). 5 - 8

Full access

Diane L. Reidy-Lagunes

, liver-directed therapies, and systemic therapies. Cytotoxic therapies, such as temozolomide, fluorouracil, oxaliplatin, and streptozocin-based chemotherapy regimens, are active against some pancNETs, and can play a role in the palliation of patients with

Full access

Yifan Wang, Adeline Cuggia, Alain Pacis, Jean-Christian Boileau, Victoria A. Marcus, Zu-Hua Gao, George Chong, William D. Foulkes, and George Zogopoulos

patient was treated with FOLFIRINOX (5-FU/folinic acid/irinotecan/oxaliplatin), but his disease progressed after 6 cycles ( Figure 1A ). He received gemcitabine/nab-paclitaxel as second-line treatment and experienced a partial response. However, he

Full access

Caitlin A. Hester, Giampaolo Perri, Laura R. Prakash, Jessica E. Maxwell, Naruhiko Ikoma, Michael P. Kim, Ching-Wei D. Tzeng, Brandon Smaglo, Robert Wolff, Milind Javle, Michael J. Overman, Jeffrey E. Lee, and Matthew H.G. Katz

radiographic evidence of acute pancreatitis ( Figure 1 ). Figure 1. Study flow diagram. Abbreviations: FOLFIRINOX, 5-fluorouracil/leucovorin/oxaliplatin/irinotecan; Gem/Nab-paclitaxel, gemcitabine + nanoparticle albumin–bound paclitaxel; PDAC

Full access

Liqin Zhu, Liyuan Li, Laura Hamel, and Dolores Lopez-Terrada

lines whose parental tumors did not respond to HB standard-of-care cisplatin. They showed the same resistance to cisplatin as well as 2 other platinum-based drugs, carboplatin and oxaliplatin. PDOs derived from 2 matched primary and metastatic tumors

Full access

Rahel Demisse, Neha Damle, Edward Kim, Jun Gong, Marwan Fakih, Cathy Eng, Leslie Oesterich, Madison McKenny, Jingran Ji, James Liu, Ryan Louie, Kit Tam, Sepideh Gholami, Wissam Halabi, Arta Monjazeb, Farshid Dayyani, and May Cho

involvement. Given his history of radiation for prostate cancer and the presence of baseline neuropathy, he was a poor candidate for neoadjuvant chemoradiation or neoadjuvant FOLFOX (folinic acid, fluorouracil, oxaliplatin). After an in-depth discussion with

Full access

Eva Battaglini, David Goldstein, Peter Grimison, Susan McCullough, Phil Mendoza-Jones, and Susanna B. Park

treatments for these cancers: taxanes (docetaxel: n=322 [32.7%]; paclitaxel: n=312 [31.6%]), platinum-based chemotherapies (oxaliplatin: n=123 [12.5%]; cisplatin: n=53 [5.4%]), thalidomide (n=87; 8.8%), and bortezomib (n=82; 8.3%). One-quarter of respondents